This reports provides a data-driven overview of the current and future competitive landscape in Rosacea therapeutics.
The publisher's Rosacea: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Synopsis
- In 2022, there will be more than 47 million diagnosed prevalent cases of rosacea across 16 pharmaceutical markets.
- There are 10 FDA approved branded marketed drugs for the treatment of rosacea.
- The rosacea pipeline consists of over 32 pharmaceuticals spanning all stages of development, with approximately 50% of drugs in early-stage development.
- Commercial sponsors dominate clinical trial development in rosacea, with the US emerging as the key countries for conducting trials in rosacea.
- Deals involving acquisition of rosacea assets were the most common type of deals globally.
- Only three players are developing products for the treatment of rosacea in the late-stage suggesting very limited change in the market scenario in immediate future.
Scope
The publisher's Rosacea: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Rosacea market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Rosacea market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pipeline Drugs Assessment
6 Clinical Trials Assessment
7 Deals Landscape
8 Commercial Assessment
10 Appendix